NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors of antibodies, enzymes or nanoparticles. These AMFA-modified therapeutics will target patients suffering from lysosomal storage disorders, cancers, inflammatory or immune diseases.

Our objectives
Based on AMFA

NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA.

The main application

is the engineering of recombinant proteins like antibodies or enzymes for better therapies.

Development

NanoMedSyn develops engineered therapeutics in-house and in partnership.